BACKGROUND: Medicare data indicate that black hemodialysis patients receive greater doses of erythropoietin (EPO) than white patients when achieving similar hemoglobin levels. We confirmed and evaluated this observed association between race and EPO dose. STUDY DESIGN: Cross-sectional cohort study. SETTING & PARTICIPANTS: Primary Medicare-insured white (57%) and black (43%) adult long-term hemodialysis patients treated by Fresenius Medical Care who received EPO from January 1 to 31, 2004 (N = 44,721). PREDICTOR: White/black race. OUTCOMES: Average weekly EPO dose. MEASUREMENTS: Associations between race and baseline demographic and laboratory variables were evaluated by using logistic and linear regression models. Correlates of log-transformed weekly EPO dose were determined using linear regression models. RESULTS: Black patients received 12.6% more EPO than white patients (95% limits, 10.9% to 14.3%; P < 0.001). This racial difference in EPO dose was observed across similar hemoglobin levels despite fewer catheters (P < 0.001) and fewer prior hospitalization events in black patients (P = 0.002). Black patients were younger and had larger body size and greater albumin and biointact parathyroid hormone levels, but lower equilibrated Kt/V and white blood cell counts (all P < 0.001). In the 95th percentile of EPO dose (those receiving > 60,000 U/wk), there was a greater proportion of black patients (6% of total black population compared with only 4% in all white patients; P < 0.001). The difference in EPO dose between black and white patients was modified by age and was significant at ages younger than 45 and 65 years or older. LIMITATIONS: Observational study limited to white and black adult Medicare patients only, correlating with EPO doses from a single month, without adjustment for comorbid conditions. CONCLUSIONS: Black patients were administered approximately 12% greater EPO doses than white patients while achieving similar hemoglobin levels. We identified variables that differed across race that may explain this difference, but they were either not actionable or presented limited opportunity for intervention. Additional studies are needed to define a physiological (or pathological) basis for these observations.
BACKGROUND: Medicare data indicate that black hemodialysis patients receive greater doses of erythropoietin (EPO) than white patients when achieving similar hemoglobin levels. We confirmed and evaluated this observed association between race and EPO dose. STUDY DESIGN: Cross-sectional cohort study. SETTING & PARTICIPANTS: Primary Medicare-insured white (57%) and black (43%) adult long-term hemodialysis patients treated by Fresenius Medical Care who received EPO from January 1 to 31, 2004 (N = 44,721). PREDICTOR: White/black race. OUTCOMES: Average weekly EPO dose. MEASUREMENTS: Associations between race and baseline demographic and laboratory variables were evaluated by using logistic and linear regression models. Correlates of log-transformed weekly EPO dose were determined using linear regression models. RESULTS: Black patients received 12.6% more EPO than white patients (95% limits, 10.9% to 14.3%; P < 0.001). This racial difference in EPO dose was observed across similar hemoglobin levels despite fewer catheters (P < 0.001) and fewer prior hospitalization events in black patients (P = 0.002). Black patients were younger and had larger body size and greater albumin and biointact parathyroid hormone levels, but lower equilibrated Kt/V and white blood cell counts (all P < 0.001). In the 95th percentile of EPO dose (those receiving > 60,000 U/wk), there was a greater proportion of black patients (6% of total black population compared with only 4% in all white patients; P < 0.001). The difference in EPO dose between black and white patients was modified by age and was significant at ages younger than 45 and 65 years or older. LIMITATIONS: Observational study limited to white and black adult Medicare patients only, correlating with EPO doses from a single month, without adjustment for comorbid conditions. CONCLUSIONS: Black patients were administered approximately 12% greater EPO doses than white patients while achieving similar hemoglobin levels. We identified variables that differed across race that may explain this difference, but they were either not actionable or presented limited opportunity for intervention. Additional studies are needed to define a physiological (or pathological) basis for these observations.
Authors: Areef Ishani; Haifeng Guo; Thomas J Arneson; David T Gilbertson; Lih-Wen Mau; Suying Li; Stephan Dunning; Allan J Collins Journal: J Am Soc Nephrol Date: 2009-04-23 Impact factor: 10.121
Authors: Vimal K Derebail; Patrick H Nachman; Nigel S Key; Heather Ansede; Ronald J Falk; Abhijit V Kshirsagar Journal: J Am Soc Nephrol Date: 2010-01-07 Impact factor: 10.121
Authors: Vimal K Derebail; Eduardo K Lacson; Abhijit V Kshirsagar; Nigel S Key; Susan L Hogan; Raymond M Hakim; Ann Mooney; Chinu M Jani; Curtis Johnson; Yichun Hu; Ronald J Falk; J Michael Lazarus Journal: J Am Soc Nephrol Date: 2014-01-23 Impact factor: 10.121
Authors: Kevin F Erickson; Yuanchao Zheng; Wolfgang C Winkelmayer; Vivian Ho; Jay Bhattacharya; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2016-11-09 Impact factor: 8.237
Authors: Jesse L Roach; Marc N Turenne; Richard A Hirth; John R C Wheeler; Kathryn S Sleeman; Joseph M Messana Journal: Am J Kidney Dis Date: 2010-11 Impact factor: 8.860
Authors: Vimal K Derebail; Patrick H Nachman; Nigel S Key; Heather Ansede; Ronald J Falk; Wayne D Rosamond; Abhijit V Kshirsagar Journal: Kidney Int Date: 2011-08-17 Impact factor: 10.612
Authors: Guofen Yan; Keith C Norris; Tom Greene; Alison J Yu; Jennie Z Ma; Wei Yu; Alfred K Cheung Journal: Clin J Am Soc Nephrol Date: 2014-06-19 Impact factor: 8.237
Authors: Marc N Turenne; Elizabeth L Cope; Shannon Porenta; Purna Mukhopadhyay; Douglas S Fuller; Jeffrey M Pearson; Claudia Dahlerus; Brett Lantz; Francesca Tentori; Bruce M Robinson Journal: J Am Soc Nephrol Date: 2014-10-09 Impact factor: 10.121
Authors: Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani Journal: PLoS One Date: 2010-02-16 Impact factor: 3.240